scholarly journals Activity of Praziquantel Enantiomers and Main Metabolites against Schistosoma mansoni

2014 ◽  
Vol 58 (9) ◽  
pp. 5466-5472 ◽  
Author(s):  
Isabel Meister ◽  
Katrin Ingram-Sieber ◽  
Noemi Cowan ◽  
Matthew Todd ◽  
Murray N. Robertson ◽  
...  
Keyword(s):  
Schistosoma Mansoni ◽  
Significant Role ◽  
Worm Burden ◽  
Racemic Mixture ◽  
Content Type ◽  
Effector Molecule ◽  
Oral Doses ◽  
Newly Transformed Schistosomula

ABSTRACTA racemic mixture ofRandSenantiomers of praziquantel (PZQ) is currently the treatment of choice for schistosomiasis. Though theSenantiomer and the metabolites are presumed to contribute only a little to the activity of the drug, in-depth side-by-side studies are lacking. The aim of this study was to investigate thein vitroactivities of PZQ and its main metabolites, namely,R- andS-cis- andR- andS-trans-4′-hydroxypraziquantel, against adult worms and newly transformed schistosomula (NTS). Additionally, we explored thein vivoactivity and hepatic shift (i.e., the migration of the worms to the liver) produced by each PZQ enantiomer in mice. Fifty percent inhibitory concentrations ofR-PZQ,S-PZQ, andR-trans- andR-cis-4′-hydroxypraziquantel of 0.02, 5.85, 4.08, and 2.42 μg/ml, respectively, for adultS. mansoniwere determinedin vitro. S-trans- andS-cis-4′-hydroxypraziquantel were not active at 100 μg/ml. These results are consistent with microcalorimetry data and studies with NTS.In vivo, single 400-mg/kg oral doses ofR-PZQ andS-PZQ achieved worm burden reductions of 100 and 19%, respectively. Moreover, worms treatedin vivowithS-PZQ displayed an only transient hepatic shift and returned to the mesenteric veins within 24 h. Our data confirm thatR-PZQ is the main effector molecule, whileS-PZQ and the metabolites do not play a significant role in the antischistosomal properties of PZQ.

scholarly journals Antischistosomal Activities of Mefloquine-Related Arylmethanols

2012 ◽  
Vol 56 (6) ◽  
pp. 3207-3215 ◽  
Author(s):  
Katrin Ingram ◽  
William Ellis ◽  
Jennifer Keiser
Keyword(s):  
Body Weight ◽  
Worm Burden ◽  
Structural Features ◽  
Content Type ◽  
Antischistosomal Activity ◽  
Oral Doses ◽  
Related Compounds ◽  
Insight Into

ABSTRACTInteresting antischistosomal properties have been documented for the antimalarial mefloquine, a 4-quinolinemethanol. We evaluated the antischistosomal activities of nine mefloquine-related compounds belonging to the 4-pyridinemethanols, 9-phenanthrenmethanols, and 4-quinolinemethanols. Eight compounds revealed high activities againstSchistosoma mansoni in vitro, with two drugs (the 4-quinolinemethanols WR7573 and WR7930) characterized by significantly lower half-maximal inhibitory concentrations (IC50s) (2.7 and 3.5 μM, respectively) compared to mefloquine (11.4 μM). Mefloquine and WR7930 showed significantly decreased IC50s when incubated in the presence of hemoglobin. High worm burden reductions (WBR) were obtained with enpiroline (WBR, 82.7%; dosage, 200 mg/kg of body weight) and itsthreoisomers (+)-threo(WBR, 100%) and (−)-threo(WBR, 89%) and with WR7930 (WBR, 87%; dosage, 100 mg/kg) against adultS. mansoniin mice. Furthermore, excellentin vitroandin vivoantischistosomal activity was observed for two WR7930-related structures (WR29252 and WR7524). In addition, mefloquine (WBR, 81%), enpiroline (WBR, 77%), and WR7930 (WBR, 100%) showed high activities againstS. haematobiumharbored in mice following single oral doses of 200 mg/kg. These results provide a deeper insight into the structural features of the arylmethanols that rule antischistosomal activity. Further studies should be launched with enpiroline and WR7930.

scholarly journals Activities ofN,N′-Diarylurea MMV665852 Analogs against Schistosoma mansoni

2015 ◽  
Vol 59 (4) ◽  
pp. 1935-1941 ◽  
Author(s):  
Noemi Cowan ◽  
Philipp Dätwyler ◽  
Beat Ernst ◽  
Chunkai Wang ◽  
Jonathan L. Vennerstrom ◽  
...  
Keyword(s):  
Physicochemical Properties ◽  
Schistosoma Mansoni ◽  
In Silico ◽  
Worm Burden ◽  
Unmet Need ◽  
Intestinal Wall ◽  
Content Type ◽  
Pharmacokinetic Properties

ABSTRACTThere is an unmet need to discover and develop novel antischistosomal drugs. As exemplified by MMV665852,N,N′-diarylureas have recently emerged as a promising antischistosomal chemotype. In this study, we evaluated the structure-activity relationships of 46 commercially available analogs of MMV665852 on newly transformed schistosomula (NTS) and adultSchistosoma mansoniwormsin vitro. Active compounds were evaluated with a cytotoxicity assay,in silicocalculations, metabolic stability studies, and anin vivoassay with mice harboring adultS. mansoniworms. Of the 46 compounds tested at 33.3 μM, 13 and 14 compounds killed NTS and adult worms, respectively, within 72 h. Nine compounds had 90% inhibitory concentrations (IC90s) of ≤10 μM against adult worms, with selectivity indexes of ≥2.8. Their physicochemical properties and permeation through an artificial membrane indicated good to moderate intestinal absorption. Their metabolic stabilities ranged from low to high. Despite satisfactoryin vitroresults andin silicopredictions, only one compound resulted in a statistically significant worm burden reduction (66%) after administration of a single oral dose of 400 mg/kg of body weight toS. mansoni-infected mice. Worm burden reductions of 0 to 43% were observed for the remaining eight compounds tested. In conclusion, several analogs of theN,N′-diarylurea MMV665852 had high efficacy againstS. mansoniin vitroand favorable physicochemical properties for permeation through the intestinal wall. To counteract the low efficacy observed in the mouse model, further investigations should focus on identifying compounds with improved solubility and pharmacokinetic properties.

scholarly journals Activities of Quinoxaline, Nitroquinoxaline and [1,2,4]Triazolo[4,3-a]quinoxaline Analogs of MMV007204 against Schistosoma mansoni

2020 ◽  
Author(s):  
Stefan L. Debbert ◽  
Mikaela J. Hintz ◽  
Christian J. Bell ◽  
Kenya R. Earl ◽  
Grant E. Forsythe ◽  
...  
Keyword(s):  
Schistosoma Mansoni ◽  
Worm Burden ◽  
New Drugs ◽  
Parasitic Disease ◽  
Quinoxaline Derivative ◽  
Pharmacokinetic Properties ◽  
Malaria Box ◽  
Newly Transformed Schistosomula

The reliance on one drug, praziquantel, to treat the parasitic disease schistosomiasis in millions of people a year shows the need to further develop a pipeline of new drugs to treat this disease. Recently, an antimalarial quinoxaline derivative (MMV007204) from the Medicines for Malaria Venture (MMV) Malaria Box demonstrated promise against Schistosoma mansoni. In this study, 47 synthesized compounds containing quinoxaline moieties were first assayed against the larval stage of this parasite, newly transformed schistosomula (NTS); of these, 16 killed over 70% NTS at 10 μM. Further testing against NTS and adult S. mansoni yielded three compounds with 50% inhibitory concentrations (IC50s) of ≤ 0.31 μM against adult S. mansoni and selectivity indices of ≥ 8.9. Administration of these compounds as a single oral dose of 400 mg/kg of body weight to S. mansoni-infected mice yielded only moderate worm burden reduction (WBR) (9.3% – 46.3%). The discrepancy between these compounds’ good in vitro activities and their poor in vivo activities indicates that optimization of their pharmacokinetic properties may yield compounds with greater bioavailabilities and better antischistosomiasis activities in vivo.

scholarly journals In VivoActivity of Aryl Ozonides against Schistosoma Species

2011 ◽  
Vol 56 (2) ◽  
pp. 1090-1092 ◽  
Author(s):  
Jennifer Keiser ◽  
Katrin Ingram ◽  
Mireille Vargas ◽  
Jacques Chollet ◽  
Xiaofang Wang ◽  
...  
Keyword(s):  
Schistosoma Mansoni ◽  
Worm Burden ◽  
Female Worm ◽  
Lead Compound ◽  
Content Type ◽  
Total Worm Burden

ABSTRACTWe evaluated thein vivoantischistosomal activities of 11 structurally diverse synthetic peroxides. Of all compounds tested, ozonide (1,2,4-trioxolane) OZ418 had the highest activity against adultSchistosoma mansoni, with total and female worm burden reductions of 80 and 90% (P< 0.05), respectively. Furthermore, treatment ofS. haematobium-infected mice with OZ418 reduced the total worm burden by 86%. In conclusion, OZ418 is a promising antischistosomal lead compound.

scholarly journals Enantiomers of Nifurtimox Do Not Exhibit Stereoselective Anti-Trypanosoma cruzi Activity, Toxicity, or Pharmacokinetic Properties

2015 ◽  
Vol 59 (6) ◽  
pp. 3645-3647 ◽  
Author(s):  
Carolina B. Moraes ◽  
Karen L. White ◽  
Stéphanie Braillard ◽  
Catherine Perez ◽  
Junghyun Goo ◽  
...  
Keyword(s):  
Trypanosoma Cruzi ◽  
Chagas Disease ◽  
Murine Model ◽  
Therapeutic Benefit ◽  
Racemic Mixture ◽  
Content Type ◽  
Pharmacokinetic Properties

ABSTRACTWith the aim of improving the available drugs for the treatment of Chagas disease, individual enantiomers of nifurtimox were characterized. The results indicate that the enantiomers are equivalent in theirin vitroactivity against a panel ofTrypanosoma cruzistrains;in vivoefficacy in a murine model of Chagas disease;in vitrotoxicity and absorption, distribution, metabolism, and excretion characteristics; andin vivopharmacokinetic properties. There is unlikely to be any therapeutic benefit of an individual nifurtimox enantiomer over the racemic mixture.

scholarly journals Trematocidal Activity of Praziquantel and Artemisinin Derivatives: In Vitro and In Vivo Investigations with Adult Echinostoma caproni

2006 ◽  
Vol 50 (2) ◽  
pp. 803-805 ◽  
Author(s):  
Jennifer Keiser ◽  
Reto Brun ◽  
Bernard Fried ◽  
Jürg Utzinger
Keyword(s):  
Body Weight ◽  
Worm Burden ◽  
Echinostoma Caproni ◽  
Artemisinin Derivatives ◽  
Exposure Response ◽  
Oral Doses

ABSTRACT We examined the effects of praziquantel and the artemisinins on adult Echinostoma caproni. In vitro, both praziquantel and the artemisinins exhibited exposure-response relationships. In vivo, worm burden reductions of 100% were achieved with single oral doses of praziquantel, artesunate, and artemether at 50, 700, and 1,100 mg/kg of body weight, respectively.

scholarly journals In VivoAntimalarial Activity and Mechanisms of Action of 4-Nerolidylcatechol Derivatives

2015 ◽  
Vol 59 (6) ◽  
pp. 3271-3280 ◽  
Author(s):  
Luiz Francisco Rocha e Silva ◽  
Karla Lagos Nogueira ◽  
Ana Cristina da Silva Pinto ◽  
Alejandro Miguel Katzin ◽  
Rodrigo A. C. Sussmann ◽  
...  
Keyword(s):  
Blood Plasma ◽  
Antimalarial Activity ◽  
Isoprenoid Biosynthesis ◽  
Metabolic Labeling ◽  
Mouse Blood ◽  
Content Type ◽  
Improved Stability ◽  
Oral Doses

ABSTRACT4-Nerolidylcatechol (1) is an abundant antiplasmodial metabolite that is isolated fromPiper peltatumroots.O-Acylation orO-alkylation of compound1provides derivatives exhibiting improved stability and significantin vitroantiplasmodial activity. The aim of this work was to study thein vitroinhibition of hemozoin formation, inhibition of isoprenoid biosynthesis inPlasmodium falciparumcultures, andin vivoantimalarial activity of several 4-nerolidylcatechol derivatives. 1,2-O,O-Diacetyl-4-nerolidylcatechol (2) inhibitedin vitrohemozoin formation by up to 50%. In metabolic labeling studies using [1-(n)-3H]geranylgeranyl pyrophosphate, diester2significantly inhibited the biosynthesis of isoprenoid metabolites ubiquinone8, menaquinone4, and dolichol12in cultures ofP. falciparum3D7. Similarly, 2-O-benzyl-4-nerolidylcatechol (3) significantly inhibited the biosynthesis of dolichol12.P. falciparumin vitroprotein synthesis was not affected by compounds2or3. At oral doses of 50 mg per kg of body weight per day, compound2suppressedPlasmodium bergheiNK65 in infected BALB/c mice by 44%. Thisin vivoresult for derivative2represents marked improvement over that obtained previously for natural product1. Compound2was not detected in mouse blood 1 h after oral ingestion or in mixtures with mouse blood/blood plasmain vitro. However, it was detected afterin vitrocontact with human blood or blood plasma. Derivatives of 4-nerolidylcatechol exhibit parasite-specific modes of action, such as inhibition of isoprenoid biosynthesis and inhibition of hemozoin formation, and they therefore merit further investigation for their antimalarial potential.

scholarly journals Therapeutic Effect of Diminazene Aceturate on Parasitic Blood Fluke Schistosoma mansoni Infection

2020 ◽  
Vol 64 (11) ◽  
Author(s):  
Mariana G. de Brito ◽  
Ana C. Mengarda ◽  
George L. Oliveira ◽  
Maria E. Cirino ◽  
Tais C. Silva ◽  
...  
Keyword(s):  
Schistosoma Mansoni ◽  
Chronic Infection ◽  
Worm Burden ◽  
Egg Production ◽  
Laser Scanning Microscopy ◽  
Early Infection ◽  
Blood Fluke ◽  
Serum Aminotransferase ◽  
Content Type

ABSTRACT Praziquantel is currently the only drug available to treat schistosomiasis, a disease of enormous public health significance caused by a blood fluke of the genus Schistosoma. Diminazene, a drug approved by the FDA, has been successfully used to treat diseases caused by blood protozoan parasites. In this study, we evaluated the antiparasitic properties of diminazene against Schistosoma mansoni ex vivo and in mice harboring either chronic or early S. mansoni infections. In vitro, we monitored phenotypic and tegumental changes as well as the effects of the drug on pairing and egg production. In mice infected with either adult (chronic infection) or immature (early infection) worms, diminazene was administered intraperitoneally (10 to 100 mg/kg of body weight) or by oral gavage (100 to 400 mg/kg), and we studied the influence of the drug on worm burden and egg production. Liver and spleen pathologies and serum aminotransferase levels were also analyzed. In vitro, 50% effective concentrations (EC50) and EC90 revealed that diminazene is able to kill both immature and adult parasites, and its effect was time and concentration dependent. In addition, confocal laser scanning microscopy showed morphological alterations in the teguments of schistosomes. In an animal model, the influence of the drug on worm burden, egg production, hepatomegaly, and splenomegaly depended on the dosing regimen applied and the route of administration. Diminazene also caused a significant reduction in aminotransferase levels. Comparatively, diminazene treatment was more effective in chronic infection than in early infection. In tandem, our study revealed that diminazene possesses anthelmintic properties and inhibits liver injury caused by Schistosoma eggs.

scholarly journals Immunohistochemical Investigations of Treatment with Ro 13-3978, Praziquantel, Oxamniquine, and Mefloquine in Schistosoma mansoni-Infected Mice

2017 ◽  
Vol 61 (12) ◽  
Author(s):  
Gordana Panic ◽  
Marie-Thérèse Ruf ◽  
Jennifer Keiser
Keyword(s):  
T Cells ◽  
B Cells ◽  
Schistosoma Mansoni ◽  
Parasite Clearance ◽  
Drug Candidate ◽  
Minimal Cell ◽  
Onset Of Action ◽  
Content Type

ABSTRACT To date, there is only one drug in use, praziquantel, to treat more than 250 million people afflicted with schistosomiasis, a debilitating parasitic disease. The aryl hydantoin Ro 13-3978 is a promising drug candidate with in vivo activity superior to that of praziquantel against both adult and juvenile Schistosoma mansoni organisms. Given the drug's contrasting low activity in vitro and the timing of its onset of action in vivo, it was postulated that immune-assisted parasite clearance could contribute to the drug's in vivo activity. We undertook histopathological studies to investigate this hypothesis. Infected mice were treated with an effective dose of Ro 13-3978 (100 mg/kg of body weight) and were dissected before and after the drug's in vivo onset of action. The veins and livers were excised, paraffin-embedded, and sectioned, and macrophages (IBA-1), neutrophils (Neutro), B cells (CD45R), and T cells (CD3) were stained by immunohistochemistry. For comparison, samples from infected untreated mice and mice treated with effective doses of praziquantel (400 mg/kg), oxamniquine (200 mg/kg), and mefloquine (200 mg/kg) were examined. At 24 h after treatment with Ro 13-3978, significant macrophage recruitment to the veins was observed, along with a modest increase in circulating B cells, and at 48 h, neutrophils and T cells are also present. Treatment with praziquantel and oxamniquine showed similar patterns of recruitment but with comparatively higher cellular levels, whereas mefloquine treatment resulted in minimal cell recruitment until 3 days posttreatment. Our study sheds light on the immediate immune responses to antischistosomal treatment in mice and provides further insight into immune effector mechanisms of schistosome clearance.

scholarly journals Spiroindolone That Inhibits PfATPase4 Is a Potent, Cidal Inhibitor of Toxoplasma gondii TachyzoitesIn VitroandIn Vivo

2013 ◽  
Vol 58 (3) ◽  
pp. 1789-1792 ◽  
Author(s):  
Ying Zhou ◽  
Alina Fomovska ◽  
Stephen Muench ◽  
Bo-Shiun Lai ◽  
Ernest Mui ◽  
...  
Keyword(s):  
Body Weight ◽  
Toxoplasma Gondii ◽  
Inhibitory Concentration ◽  
Parasite Burden ◽  
Content Type ◽  
Medicine Development ◽  
Lead Candidate ◽  
Oral Doses

ABSTRACTHere, we show that spiroindolone, an effective treatment for plasmodia, is also active againstToxoplasma gondiitachyzoites.In vitro, spiroindolone NITD609 is cidal for tachyzoites (50% inhibitory concentration [IC50], 1μM) and not toxic to human cells at ≥10μM. Two daily oral doses of 100 mg/kg of body weight reduced the parasite burden in mice by 90% (P= 0.002), measured 3 days after the last dose. This inhibition ofT. gondiitachyzoitesin vitroandin vivoindicates that spiroindolone is a promising lead candidate for further medicine development.

Sign in / Sign up

Export Citation Format

Share Document